Data on the anti-cancer activity of Histogen's multipotent compositions has been
published in the July 2013 Journal of Cancer Therapy, showing reduction in multiple skin cancer cell lines in vitro.
Histogen CEO Gail K. Naughton, Ph.D. presents at the 3rd Annual Regen Med Partnering Forum, part of the Stem Cell Meeting on the Mesa.
- Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally
- Multipotent Stem Cell Proteins Support Soft Tissue Regeneration
- Multipotent Stem Cell Proteins Support Rejuvenation while Inhibiting Skin Cancer
- Histogen to present at 2013 STEM CELL MEETING ON THE MESA
© Histogen Inc., CA 92121